[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355124-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355124-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","epigenetic-and-transcriptional-programs-define-osteosarcoma-subtypes-and-establish-targetable-vulnerabilities-research-article","Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities - Research Article","","Osteosarcoma is a genomically complex, highly heterogeneous pediatric cancer with limited therapeutic progress due to unclear oncogenic drivers. Epigenetic mechanisms are explored as drivers of distinct tumor subtypes. Chromatin-accessibility analysis identifies two osteoblast-derived cellular states with linked transcription-factor circuits controlling gene-expression programs. Multiomic single-cell data indicate coexistence within one tumor, and patient-derived xenograft models reveal state-dependent drug responses tied to survival, enabling improved combination-therapy opportunities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/epigenetic-and-transcriptional-programs-define-osteosarcoma-subtypes-and-establish-targetable-vulnerabilities-research-article/355124/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/epigenetic-and-transcriptional-programs-define-osteosarcoma-subtypes-and-establish-targetable-vulnerabilities-research-article/355124.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the two cellular states identified in osteosarcoma, and what distinguishes them?","Question",{"text":63,"@type":64},"The study identifies an “early osteoblast–derived” state enriched for transcription factors tied to early bone development and a “late osteoblast–derived” state enriched for genes involved in late bone development.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were core regulatory circuitries and enhancer elements determined?",{"text":68,"@type":64},"The work used chromatin accessibility and integrated ATAC-seq with histone H3K27ac binding analysis to pinpoint critical superenhancers and the core regulatory circuitries that govern gene-expression programs.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the epigenetically defined states relate to drug response?",{"text":72,"@type":64},"Using patient-derived xenograft models, the researchers found differential drug responses that depend on the cellular state, supporting the value of targeting these epigenetic subtypes for combination therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355124,1790219236,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":99,"preview_page_count":33,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","ReseaRch aRticle  \nEpigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities   \nEunice López-Fuentes, Andrew S. Clugston, Alex G. Lee, Leanne C. Sayles, Natalie Sorensen,  \nMaria V. Pons Ventura, Stanley G. Leung, Truc Dinh, Marcus R. Breese, and E. Alejandro Sweet-Cordero  \nOsteosarcoma is a genomically complex tumor characterized by widespread  \nstructural rearrangements. This complexity has limited the development of therapeutic strategies informed by molecular mechanisms of oncogenesis. We hypothesized that epigenetic mechanisms could drive distinct subtypes of osteosarcoma. Through analysis of chromatin accessibility, we identified an “early osteoblast–derived” cell state, characterized by upregulation of transcription factors associated with early bone development, and a “late osteoblast–derived”state, characterized by upregulation of genes involved in late bone development. We then defined core regulatory circuitries governing the underlying gene expression programs in these two cell states. Multiomic single-cell analysis indicates that these cell states coexist in a single tumor. Finally, using a panel of patient-derived xenograft models, we identified differential drug responses dependent on these cellular states. These findings create opportunities for developing new combination therapy strategies for osteosarcoma treatment and underscore the value of defining epigenetic subtypes in highly genomically complex cancers.  \nSignifiCAnCE: This study identifies two distinct cellular states in osteosarcoma, driven by specific transcription factor circuitries linked to normal bone development. These epigenetically defined states demonstrate differential drug responses, are identifiable in patient samples, and are correlated with survival.  \nintRoduction  \nOsteosarcoma is an aggressive cancer that primarily affects children, adolescents, and young adults. Treatment requires local control, followed by highly toxic chemotherapy regimens that have not changed in more than 40 years (1) . Although this approach is sometimes effective for early-stage disease, osteosarcoma remains one of the pediatric cancers with the lowest survival rates, largely because of the frequent emergence of metastatic disease (2) . The main challenges in osteosarcoma research, drug discovery, and clinical treatment stem from the fact that this disease lacks clear oncogenicdriver genes; rather, it is characterized by high genomic complexity and significant intra-and intertumoral heterogeneity (3) . Thus, although copy-number gains, deletions, and structural rearrangements in specific oncogenic drivers are common, recurrent point mutations in targetable oncogenes are few (4). Furthermore, intratumoral heterogeneity has impeded efforts to subclassify osteosarcoma based on underlying molecular features, optimize treatments based on key molecular characteristics, and predict therapeutic response. Although recent studies provided evidence that  \nDivision of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California.  \nCorresponding Author: E. Alejandro Sweet-Cordero, University of California, 1550 4th Street, Rock Hall Room 384D, San Francisco, CA 94158.  \n[E-mail: Alejandro.Sweet-Cordero@ucsf.edu](E-mail: Alejandro.Sweet-Cordero@ucsf.edu)[ ](E-mail: Alejandro.Sweet-Cordero@ucsf.edu)Cancer Discov 2026;16:296–319  \ndoi: 10. 1158/2159-8290 . CD-25-0237  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.©2025 The Authors; Published by the American Association for Cancer Research  \npatients with osteosarcoma can be clustered based on transcriptional programs (5–7), the underlying molecular basis for this clustering remains unclear.  \nEpigenetic programs have been shown to play an important role in the initiation and progression of many cancers (8). DNA methylatio","cbCaisOm8mzI4T6S","https://ap.wps.com/l/cbCaisOm8mzI4T6S","pdf",61967304,24,"English","# Significance\n## Overview and rationale\n## Epigenetic landscape and methods\n## Findings: cellular states and regulatory circuits\n## Therapeutic implications and validation","[{\"question\":\"What are the two cellular states identified in osteosarcoma, and what distinguishes them?\",\"answer\":\"The study identifies an “early osteoblast–derived” state enriched for transcription factors tied to early bone development and a “late osteoblast–derived” state enriched for genes involved in late bone development.\"},{\"question\":\"How were core regulatory circuitries and enhancer elements determined?\",\"answer\":\"The work used chromatin accessibility and integrated ATAC-seq with histone H3K27ac binding analysis to pinpoint critical superenhancers and the core regulatory circuitries that govern gene-expression programs.\"},{\"question\":\"How do the epigenetically defined states relate to drug response?\",\"answer\":\"Using patient-derived xenograft models, the researchers found differential drug responses that depend on the cellular state, supporting the value of targeting these epigenetic subtypes for combination therapy.\"}]","Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities - Research Article | PDF",1790116171,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b15985be25436ab0793f75968067575b.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc3314399e280f683994ac0bc86b1d1e.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12e438886fa41676fb3b0f18d08ede93.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e99837e5a035362823f1abdea5eb7d61.webp",980,1311]